Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 82
Filtrar
1.
BMC Infect Dis ; 21(1): 966, 2021 Sep 17.
Artículo en Inglés | MEDLINE | ID: mdl-34535079

RESUMEN

BACKGROUND: Legionella spp. are ubiquitous freshwater bacteria responsible for rare but potentially severe cases of Legionnaires' disease (LD). Legionella sainthelensi is a non-pneumophila Legionella species that was first isolated in 1980 from water near Mt. St-Helens (USA). Although rare cases of LD caused by L. sainthelensi have been reported, very little data is available on this pathogen. CASE PRESENTATION: We describe the first documented case of severe bilateral pleuropneumonia caused by L. sainthelensi. The patient was a 35-year-old woman with Sharp's syndrome treated with long-term hydroxychloroquine and corticosteroids who was hospitalized for an infectious illness in a university hospital in Reunion Island (France). The patient's clinical presentation was complicated at first (bilateral pneumonia, multiloculated pleural effusion, then bronchopleural fistula) but her clinical condition eventually improved with the reintroduction of macrolides (spiramycin) in intensive care unit. Etiological diagnosis was confirmed by PCR syndromic assay and culture on bronchoalveolar lavage. CONCLUSIONS: To date, only 14 documented cases of L. sainthelensi infection have been described worldwide. This pathogen is difficult to identify because it is not or poorly detected by urinary antigen and molecular methods (like PCR syndromic assays that primarily target L. pneumophila and that have only recently been deployed in microbiology laboratories). Pneumonia caused by L. sainthelensi is likely underdiagnosed as a result. Clinicians should consider the possibility of non-pneumophila Legionella infection in patients with a compatible clinical presentation when microbiological diagnostic tools targeted L. pneumophila tested negative.


Asunto(s)
Legionella pneumophila , Legionella , Enfermedad de los Legionarios , Pleuroneumonía , Adulto , Femenino , Humanos , Legionella/genética , Legionella pneumophila/genética , Enfermedad de los Legionarios/diagnóstico , Enfermedad de los Legionarios/tratamiento farmacológico , Pleuroneumonía/diagnóstico , Pleuroneumonía/tratamiento farmacológico
2.
Arch. argent. pediatr ; 118(2): e208-e210, abr. 2020.
Artículo en Español | LILACS, BINACIS | ID: biblio-1100488

RESUMEN

La glomerulonefritis aguda desencadenada por Streptococcus pneumoniae es una patología de baja prevalencia. Existen diversos reportes que comunican distintas cepas nefritogénicas; sin embargo, la 6C ha sido escasamente señalada como tal.Se presenta el caso de un paciente de 4 años, quien ingresó a Terapia Intensiva con pleuroneumonía por Streptococcus pneumoniae serotipo 6C y desarrolló, de modo concomitante, edemas, hipertensión arterial, hematuria, proteinuria, disminución del filtrado glomerular y del nivel de complemento C3. Se diagnosticó glomerulonefritis aguda. Su evolución fue satisfactoria en un breve plazo. Esta patología, por lo general, es de curso transitorio y benigno; sin embargo, en ocasiones, puede complicar la evolución de un paciente críticamente enfermo, por lo cual se hace necesario tenerla entre los diagnósticos diferenciales para considerar.


Acute glomerulonephritis caused by Streptococcuspneumoniaeis a low prevalence pathology. There are several reports communicating different nephritogenic serotypes, however, 6C has been scarcely indicated as such. It is presented the case of a 4-year-old patient who entered Intensive Therapy Unit with pleuropneumonia due to Streptococcuspneumoniae serotype 6C and concomitantly developed edemas, arterial hypertension, hematuria, proteinuria, decreased glomerular filtration rate and C3 complement level. Acute glomerulonephritis was diagnosed. His evolution was satisfactory in a short time. This pathology is usually of a transitory and benign course; however, sometimes it can potentially complicate the evolution of a critically ill patient, so it is necessary to have it among the differential diagnoses to consider.


Asunto(s)
Humanos , Masculino , Preescolar , Pleuroneumonía/diagnóstico , Glomerulonefritis , Pleuroneumonía/tratamiento farmacológico , Streptococcus pneumoniae , Diagnóstico Diferencial
3.
Pol J Vet Sci ; 23(4): 605-610, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-33480497

RESUMEN

The pathogenesis of porcine contagious pleuropneumonia is poorly understood. In the present study, a mouse model of intranasal infection by Actinobacillus pleuropneumoniae (App) was used to examine lung inflammation. The pathogical results of lung tissues showed that App-infected mice showed dyspnea and anorexia, with severe damage by acute hemorrhage, and infiltration of eosinophils and lymphocytes, as well as increased expression of caspase-1 p20, interleukin (IL)-1ß, IL-6, IL-8, IL-18 and tumor necrosis factor (TNF)-α. Caspase-1 inhibitors reduced both lung tissue damage and the expression of caspase-1 p20, IL-1ß, IL-6, IL-8, TNF-α and IL-18 in infected mice. These findings suggest that the caspase-1 dependent pyroptosis involved in the pathogenesis of the mouse pleuropneumonia caused by App and the inhibition of caspase-1 reduced the lung injury of this pleuropneumonia.


Asunto(s)
Infecciones por Actinobacillus/tratamiento farmacológico , Actinobacillus pleuropneumoniae , Lesión Pulmonar/prevención & control , Pleuroneumonía/tratamiento farmacológico , Serpinas/farmacología , Proteínas Virales/farmacología , Infecciones por Actinobacillus/microbiología , Animales , Ratones , Pleuroneumonía/microbiología
4.
Vet Microbiol ; 219: 100-106, 2018 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-29778180

RESUMEN

To evaluate the relationship between the pharmacokinetic/pharmacodynamic (PK/PD) parameters and the antibacterial effect of cefquinome against Actinobacillus pleuropneumoniae, a tissue cage infection model was established in piglets. In this model, an initial count of A. pleuropneumoniae of approximately 106 CFU/mL was exposed to different concentrations of cefquinome after multiple administration at dosages of 0.2, 0.4, 0.8, 1, 2, 4 mg/kg body weight once a day for 3 days. Concentration of cefquinome and bacterial numbers of A. pleuropneumoniae in the tissue-cage fluid (TCF) were monitered. An inhibitory form of sigmoid maximum effect (Emax) model was used to estimate the relationship between the antibacterial effect and PK/PD indices of cefquinome against A. pleuropneumoniae. The minimum inhibitory concentration of cefquinome against A. pleuropneumoniae was 0.016 µg/mL in TCF. The total maximum antibacterial effect was a 3.96 log10 (CFU/mL) reduction. In addition, the cumulative percentage of time over a 24 h period that the drug concentration exceeds the MIC (%T > MIC) was the pharmacokinetic-pharmacodynamic (PK-PD) index that best correlated with the antibacterial efficacy (R2 = 0.967). The estimated %T > MIC values were 11.59, 27.49, and 59.81% for a 1/3-log10 (CFU/mL) reduction, a 2/3-log10 (CFU/mL) reduction, and a 1-log10 (CFU/mL) reduction, respectively, during the 24h administration period of cefquinome. In conclusion, cefquinome exhibits excellent antibacterial activity and time-dependent characteristics against A. pleuropneumoniae in vivo. Furthermore, these data provide meaningful guidance to optimize regimens of cefquinome to treat respiratory tract infections caused by A. pleuropneumoniae.


Asunto(s)
Infecciones por Actinobacillus/veterinaria , Actinobacillus pleuropneumoniae/efectos de los fármacos , Antibacterianos/farmacocinética , Cefalosporinas/farmacocinética , Pleuroneumonía/veterinaria , Infecciones por Actinobacillus/tratamiento farmacológico , Infecciones por Actinobacillus/microbiología , Animales , Antibacterianos/administración & dosificación , Antibacterianos/farmacología , Área Bajo la Curva , Cefalosporinas/administración & dosificación , Cefalosporinas/farmacología , Cámaras de Difusión de Cultivos , Modelos Animales de Enfermedad , Pruebas de Sensibilidad Microbiana , Pleuroneumonía/tratamiento farmacológico , Pleuroneumonía/microbiología , Porcinos
5.
Clin Microbiol Infect ; 24(12): 1339.e1-1339.e5, 2018 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-29549058

RESUMEN

OBJECTIVES: Listeria monocytogenes (Lm) is a foodborne human pathogen responsible for severe infections, including septicaemia, neurolisteriosis, and maternal-foetal and focal infections. Little is known about Lm-associated respiratory tract or lung infections. METHODS: We conducted a retrospective study of culture-proven cases of Lm pleural infections and pneumonia reported to the French National Reference Centre for Listeria from January 1993 to August 2016. RESULTS: Thirty-eight consecutive patients with pleural infection (n = 32), pneumonia (n = 5), or both (n = 1) were studied; 71% of these were men. Median age was 72 (range 29-90). Two patients presented with concomitant neurolisteriosis. All patients but one reported at least one immunosuppressive condition (97%), with a median number of 2 (range 0-5), including 29% (8/28) with current exposure to immunosuppressive therapy and 50% (17/34) with ongoing neoplasia; 75% (21/28) reported previous pleural or pulmonary disease. Antibiotic therapy mostly consisted in amoxicillin (72%) associated with aminoglycoside in 32%. Chest-tube drainage was performed in 7/19 patients with empyema (37%); 25% of the patients (7/30) required intensive care management. In-hospital mortality reached 35% and occurred after a median time interval of 4 days (range 1-33 days). Three patients had recurrence of empyema (time interval of 1 week to 4 months after treatment completion). Altogether, only 13/31 patients (42%) diagnosed with Lm respiratory infection experienced an uneventful outcome at 2-year follow-up. CONCLUSION: Lm is a rare but severe cause of pneumonia and pleural infection in older immunocompromised patients, requiring prompt diagnosis and adequate management and follow-up.


Asunto(s)
Listeriosis/complicaciones , Listeriosis/epidemiología , Enfermedades Pulmonares/epidemiología , Enfermedades Pulmonares/microbiología , Infecciones del Sistema Respiratorio/epidemiología , Adulto , Anciano , Anciano de 80 o más Años , Antibacterianos/uso terapéutico , Empiema Pleural/tratamiento farmacológico , Empiema Pleural/epidemiología , Empiema Pleural/etiología , Empiema Pleural/microbiología , Femenino , Humanos , Listeria monocytogenes/efectos de los fármacos , Listeria monocytogenes/aislamiento & purificación , Listeriosis/tratamiento farmacológico , Listeriosis/microbiología , Enfermedades Pulmonares/tratamiento farmacológico , Enfermedades Pulmonares/etiología , Masculino , Persona de Mediana Edad , Pleuroneumonía/tratamiento farmacológico , Pleuroneumonía/epidemiología , Pleuroneumonía/etiología , Pleuroneumonía/microbiología , Neumonía Bacteriana/tratamiento farmacológico , Neumonía Bacteriana/epidemiología , Neumonía Bacteriana/etiología , Neumonía Bacteriana/microbiología , Infecciones del Sistema Respiratorio/tratamiento farmacológico , Infecciones del Sistema Respiratorio/etiología , Infecciones del Sistema Respiratorio/microbiología , Estudios Retrospectivos , Sepsis/tratamiento farmacológico , Sepsis/epidemiología , Sepsis/etiología , Sepsis/microbiología
6.
Environ Toxicol Pharmacol ; 40(2): 388-96, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-26245812

RESUMEN

Chinese patent medicines play an important role in veterinary clinical use. The aim of this study is to research the anti-infection effect of Chinese patent medicine "Wuhuanghu" for the treatment of porcine infectious pleuropneumonia and to evaluate the safety of "Wuhuanghu" in order to provide a comprehensive understanding of its toxicity. The anti-infection results showed that the treatment with "Wuhuanghu" could significantly inhibit pneumonia and decrement of the pneumonia in high, medium and low doses of "Wuhuanghu" groups were 70.97%, 61.29% and 58.06% respectively. The acute toxicity test showed that rats in the highest group (5000mg/kg) had no death and no abnormal response, suggesting the LD50 of "Wuhuanghu" was more than 5000mg/kg. The subchronic toxicity study showed that hematology indexes in all groups had no obvious differences; blood biochemical index, only albumin and total cholesterol in middle and low doses of "Wuhuanghu" groups were significantly decreased when compared with control group. The clinical pathology showed that the target organ of "Wuhuanghu" was liver. The safety pharmacology study indicated that "Wuhuanghu" had no side effects on rats. In conclusion, "Wuhuanghu" has therapeutic and protective effects to porcine infectious pleuropneumonia in a dose-dependent manner and "Wuhuanghu" is a safe veterinary medicine.


Asunto(s)
Medicamentos Herbarios Chinos/administración & dosificación , Medicamentos sin Prescripción/administración & dosificación , Pleuroneumonía/veterinaria , Enfermedades de los Porcinos/tratamiento farmacológico , Animales , Relación Dosis-Respuesta a Droga , Medicamentos Herbarios Chinos/efectos adversos , Femenino , Hígado/efectos de los fármacos , Masculino , Medicamentos sin Prescripción/efectos adversos , Pleuroneumonía/tratamiento farmacológico , Pleuroneumonía/patología , Ratas , Porcinos , Enfermedades de los Porcinos/patología , Pruebas de Toxicidad Aguda , Pruebas de Toxicidad Subcrónica , Drogas Veterinarias/administración & dosificación , Drogas Veterinarias/efectos adversos
7.
Vet Microbiol ; 179(3-4): 277-86, 2015 Sep 30.
Artículo en Inglés | MEDLINE | ID: mdl-26130517

RESUMEN

Actinobacillus pleuropneumoniae is a Gram-negative bacterium and causative agent of porcine pleuropneumonia. This is a highly contagious disease that causes important economic losses to the swine industry worldwide. Penicillins are extensively used in swine production and these antibiotics are associated with high systemic clearance and low oral bioavailability. This may expose A. pleuropneumoniae to sub-inhibitory concentrations of penicillin G when the antibiotic is administered orally. Our goal was to evaluate the effect of sub-minimum inhibitory concentration (MIC) of penicillin G on the biofilm formation of A. pleuropneumoniae. Biofilm production of 13 field isolates from serotypes 1, 5a, 7 and 15 was tested in the presence of sub-MIC of penicillin G using a polystyrene microtiter plate assay. Using microscopy techniques and enzymatic digestion, biofilm architecture and composition were also characterized after exposure to sub-MIC of penicillin G. Sub-MIC of penicillin G significantly induced biofilm formation of nine isolates. The penicillin G-induced biofilms contained more poly-N-acetyl-D-glucosamine (PGA), extracellular DNA and proteins when compared to control biofilms grown without penicillin G. Additionally, penicillin G-induced biofilms were sensitive to DNase which was not observed with the untreated controls. Furthermore, sub-MIC of penicillin G up-regulated the expression of pgaA, which encodes a protein involved in PGA synthesis, and the genes encoding the envelope-stress sensing two-component regulatory system CpxRA. In conclusion, sub-MICs of penicillin G significantly induce biofilm formation and this is likely the result of a cell envelope stress sensed by the CpxRA system resulting in an increased production of PGA and other matrix components.


Asunto(s)
Actinobacillus pleuropneumoniae/efectos de los fármacos , Antibacterianos/farmacología , Biopelículas/efectos de los fármacos , Penicilina G/farmacología , Pleuroneumonía/veterinaria , Enfermedades de los Porcinos/tratamiento farmacológico , Enfermedades de los Porcinos/microbiología , Acetilglucosamina/metabolismo , Actinobacillus pleuropneumoniae/crecimiento & desarrollo , Animales , Antibacterianos/uso terapéutico , Proteínas Bacterianas/metabolismo , Biopelículas/crecimiento & desarrollo , Pruebas de Sensibilidad Microbiana , Penicilina G/uso terapéutico , Pleuroneumonía/tratamiento farmacológico , Proteínas Quinasas/metabolismo , Especificidad de la Especie , Porcinos
8.
J Vet Med Sci ; 77(4): 499-502, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25648207

RESUMEN

A one-year-old, castrated male domestic short hair cat was admitted with a history of anorexia, regurgitation and pyrexia for two days. Fever and leukocytosis were identified. There were a large soft tissue density oval mass in the caudal mediastinum on thoracic radiographs, a fluid-filled oval mass in the caudal mediastinum on ultrasonography, and left-sided and ventrally displaced and compressed esophagus on esophagram. On esophageal endoscopy, there were no esophageal abnormalities. CT findings with a fluid filled mass with rim enhancement indicated a caudal mediastinal paraesophageal abscess. The patient was treated with oral antibiotics, because the owner declined percutaneous drainage and surgery. The patient was admitted on emergency with severe respiratory distress; and ruptured abscess and deteriorated pleuropneumonia were suspected. With intensive hospitalization care and additional antibiotic therapy, the patient had full recovery.


Asunto(s)
Absceso/veterinaria , Combinación Amoxicilina-Clavulanato de Potasio/uso terapéutico , Antibacterianos/uso terapéutico , Absceso/complicaciones , Absceso/tratamiento farmacológico , Animales , Enfermedades de los Gatos , Gatos , Quimioterapia Combinada , Masculino , Metronidazol/administración & dosificación , Metronidazol/uso terapéutico , Pleuroneumonía/tratamiento farmacológico , Pleuroneumonía/etiología , Pleuroneumonía/patología , Pleuroneumonía/veterinaria , Rotura
9.
BMC Res Notes ; 7: 432, 2014 Jul 05.
Artículo en Inglés | MEDLINE | ID: mdl-24997586

RESUMEN

BACKGROUND: Capnocytophaga canimorsus is a commensal bacterium found in the saliva of dogs and cats. Clinically significant infections in humans after a bite are often associated with the presence of immune deficiency. Early recognition and appropriate treatment are crucial for patient survival. In addition, patients with immune deficiency are susceptible to serious life-threatening nosocomial infections, which may also influence the prognosis of patients with Capnocytophaga canimorsus infection. CASE PRESENTATION: A 62-year-old Caucasian female was admitted with septic shock, acute respiratory distress syndrome, acute renal failure, metabolic acidosis and disseminated intravascular coagulation after suffering two small bites from her dog. She had received a splenectomy during childhood. The patient survived after early empiric treatment with antibiotics and intensive supportive care, including ventilation support, a high dose of noradrenalin, and continuous venovenous hemodialysis applied prior to the definitive diagnosis of Capnocytophaga canimorsus sepsis. She improved within 2 weeks but, despite all efforts to prevent nosocomial infection, her hospital course was complicated by Enterococcus species and Candida albicans pleuropneumonia that prolonged her stay in the intensive care unit, and necessitated ventilation support for 2 months. CONCLUSION: Severe Capnocytophaga canimorsus sepsis may be complicated by life-threatening nosocomial infection in immunocompromized patients. The prophylactic application of antibiotics after a dog bite should be considered in high-risk individuals with immune deficiency in order to prevent both Capnocytophyga canimorsus sepsis and serious nosocomial complications.


Asunto(s)
Lesión Renal Aguda/inmunología , Mordeduras y Picaduras/inmunología , Coagulación Intravascular Diseminada/inmunología , Huésped Inmunocomprometido , Pleuroneumonía/inmunología , Síndrome de Dificultad Respiratoria/inmunología , Choque Séptico/inmunología , Lesión Renal Aguda/complicaciones , Lesión Renal Aguda/tratamiento farmacológico , Lesión Renal Aguda/microbiología , Animales , Antibacterianos/uso terapéutico , Mordeduras y Picaduras/complicaciones , Mordeduras y Picaduras/tratamiento farmacológico , Mordeduras y Picaduras/microbiología , Capnocytophaga/inmunología , Coagulación Intravascular Diseminada/complicaciones , Coagulación Intravascular Diseminada/tratamiento farmacológico , Coagulación Intravascular Diseminada/microbiología , Perros , Femenino , Humanos , Persona de Mediana Edad , Pleuroneumonía/tratamiento farmacológico , Pleuroneumonía/microbiología , Pleuroneumonía/patología , Síndrome de Dificultad Respiratoria/complicaciones , Síndrome de Dificultad Respiratoria/tratamiento farmacológico , Síndrome de Dificultad Respiratoria/microbiología , Choque Séptico/complicaciones , Choque Séptico/tratamiento farmacológico , Choque Séptico/microbiología
11.
Eur J Intern Med ; 24(6): 552-7, 2013 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-23725690

RESUMEN

OBJECTIVES: The objective of this study is to characterize the common risk factors, clinical presentation, imaging findings, treatment and outcome of nocardial infection. DESIGN AND SETTINGS: A retrospective cohort study. We reviewed the charts of all patients with nocardiosis in the Chaim Sheba Medical Center, a tertiary medical center in Israel, between the years 1996 and 2011. RESULTS: A total of 39 patients who had positive culture of Nocardia were analyzed. The majority of our patients were immunocompromised (74.5%), mostly due to corticosteroid therapy. None had HIV/AIDS. The clinical presentation was either acute or a chronic smoldering illness. The three major clinical syndromes were pleuropulmonary, neurological and skin/soft tissue infection about 20.5% each. Pathology in the lungs was seen in most of the patients by CT scan; discrete nodules and wedge shaped pleural based consolidations were the most frequent findings. Brain lesions consistent with abscesses were detected in 10 patients by brain imaging. Some cases had relapsing disease in spite of antimicrobial treatment. 25% of examined isolates were resistant to trimethoprim/sulfamethoxazole. The duration of intravenous antimicrobial treatment ranged from one month to over a year in the severe cases. One year mortality rate was 32%. CONCLUSION: Nocardiosis requires a high clinical index of suspicion in order to diagnose and treat promptly. Disease extent and bacterial susceptibility have important implications for prognosis and treatment.


Asunto(s)
Encefalitis/diagnóstico , Huésped Inmunocomprometido , Nocardiosis/diagnóstico , Pleuroneumonía/diagnóstico , Enfermedades Cutáneas Bacterianas/diagnóstico , Infecciones de los Tejidos Blandos/diagnóstico , Corticoesteroides/efectos adversos , Adulto , Anciano , Amicacina/uso terapéutico , Carbapenémicos/uso terapéutico , Ceftriaxona/uso terapéutico , Estudios de Cohortes , Encefalitis/tratamiento farmacológico , Encefalitis/epidemiología , Femenino , Humanos , Israel/epidemiología , Masculino , Persona de Mediana Edad , Nocardiosis/tratamiento farmacológico , Nocardiosis/epidemiología , Pleuroneumonía/tratamiento farmacológico , Pleuroneumonía/epidemiología , Estudios Retrospectivos , Factores de Riesgo , Enfermedades Cutáneas Bacterianas/tratamiento farmacológico , Enfermedades Cutáneas Bacterianas/epidemiología , Infecciones de los Tejidos Blandos/tratamiento farmacológico , Infecciones de los Tejidos Blandos/epidemiología , Centros de Atención Terciaria , Resultado del Tratamiento , Combinación Trimetoprim y Sulfametoxazol/uso terapéutico
12.
Aust Vet J ; 90(9): 358-62, 2012 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-22928684

RESUMEN

This report documents the treatment of a case of chronic pleuropneumonia in a 3-year-old Thoroughbred gelding. A recombinant tissue plasminogen activator (tenecteplase) and a recombinant deoxyribonucleic acidase (alphadornase) were infused into the pleural cavity as adjunctive therapy in the early stages of treatment. Instillation of fibrinolytic drugs was associated with a subjective reduction in the amount of fibrin deposition and decreased fluid accumulation within the pleural cavities. Fibrinolytic therapy may be a useful adjunctive therapy in selected cases of intrapleural disease in horses.


Asunto(s)
Fibrinolíticos/uso terapéutico , Enfermedades de los Caballos/tratamiento farmacológico , Pleuroneumonía/veterinaria , Terapia Trombolítica/veterinaria , Activador de Tejido Plasminógeno/uso terapéutico , Animales , Antibacterianos/uso terapéutico , Caballos , Masculino , Derrame Pleural/tratamiento farmacológico , Derrame Pleural/veterinaria , Pleuroneumonía/tratamiento farmacológico , Salmonelosis Animal/tratamiento farmacológico , Infecciones Estreptocócicas/tratamiento farmacológico , Infecciones Estreptocócicas/veterinaria , Streptococcus equi/aislamiento & purificación , Resultado del Tratamiento
14.
Vet Microbiol ; 156(1-2): 172-7, 2012 Apr 23.
Artículo en Inglés | MEDLINE | ID: mdl-22104584

RESUMEN

The aim of this retrospective study was to evaluate the antimicrobial resistance rates and the trend in resistance of Actinobacillus pleuropneumoniae isolated from pigs in Italy from 1994 to 2009. A total of 992 A. pleuropneumoniae isolates were tested for their susceptibility to a panel of antimicrobial agents in a disk diffusion method. Resistance to 7 drugs (amoxicillin, amoxicillin/clavulanic acid, ampicillin, cefquinome, cotrimoxazole, penicillin G and tilmicosin) showed a significant increasing trend over the time, while for 2 drugs (gentamycin and marbofloxacin) a significant decrease was observed. Resistance to the remaining 14 antimicrobial agents tested did not change significantly over the study period. Most of the isolates retained high susceptibility to antimicrobials usually effective against A. pleuropneumoniae such as amphenicols, fluoroquinolones and ceftiofur. However, high rates of resistance were observed for potentiated sulfa drugs, tetracyclines and penicillins which are currently recommended antimicrobials for pig pleuropneumonia therapy. Our results suggest the importance of continued monitoring of A. pleuropneumoniae clinical isolates in order to choose the most appropriate treatment of infections and to control the increase of resistance to currently used antimicrobials.


Asunto(s)
Infecciones por Actinobacillus/veterinaria , Actinobacillus pleuropneumoniae/efectos de los fármacos , Actinobacillus pleuropneumoniae/aislamiento & purificación , Pleuroneumonía/veterinaria , Enfermedades de los Porcinos/microbiología , Infecciones por Actinobacillus/tratamiento farmacológico , Infecciones por Actinobacillus/microbiología , Animales , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Italia , Pruebas de Sensibilidad Microbiana , Pleuroneumonía/tratamiento farmacológico , Pleuroneumonía/microbiología , Estudios Retrospectivos , Sus scrofa , Porcinos , Enfermedades de los Porcinos/tratamiento farmacológico
15.
Rev Mal Respir ; 28(3): 348-51, 2011 Mar.
Artículo en Francés | MEDLINE | ID: mdl-21482339

RESUMEN

Mycobacterium chelonae (M. chelonae) is rarely responsible for respiratory infection. This report concerns the case of an 81-year-old man with previously asymptomatic bronchiectasis, colonised by M. chelonae for 3 years. He was hospitalised for acute dyspnoea and fever due to a right hydro-pneumothorax with cavitated alveolar opacities of the right lung. Pleural fluid and bronchial aspiration were positive for M. chelonae and no other microorganisms were detected. The effusion was drained and the patient treated with clarythromycin and amikacin. The radiological abnormalities improved but the patient's general condition remained poor. Treatment was continued for 11 months. Because of the absence of any other bacteria, clinical deterioration following broad-spectrum antibiotics and stabilisation of the lesions after anti-mycobacterial treatment, our diagnosis was severe M. chelonae pleuro-pneumonia in an immunocompetent patient.


Asunto(s)
Infecciones por Mycobacterium no Tuberculosas/complicaciones , Mycobacterium chelonae/aislamiento & purificación , Pleuroneumonía/microbiología , Anciano de 80 o más Años , Amicacina/uso terapéutico , Antibacterianos/uso terapéutico , Bronquiectasia/microbiología , Claritromicina/uso terapéutico , Drenaje , Quimioterapia Combinada , Humanos , Masculino , Infecciones por Mycobacterium no Tuberculosas/diagnóstico , Infecciones por Mycobacterium no Tuberculosas/tratamiento farmacológico , Infecciones por Mycobacterium no Tuberculosas/cirugía , Pleuroneumonía/diagnóstico , Pleuroneumonía/tratamiento farmacológico , Pleuroneumonía/cirugía , Factores de Riesgo , Resultado del Tratamiento
18.
Acta Reumatol Port ; 34(4): 628-32, 2009.
Artículo en Portugués | MEDLINE | ID: mdl-20087268

RESUMEN

Cardiopulmonary manifestations of adult-onset Still's disease (AOSD) include pericarditis, pleural effusion, transient pulmonary infiltrates, pulmonary interstitial disease and myocarditis. Serositis are common but pneumonitis and myocarditis are not and bring elevated risk of mortality. They may manifest on disease onset or flares. Previously reported cases were treated with high-dose glucocorticoids and immunosupressants and, when refractory, intravenous immunoglobulin (IVIG). We report an AOSD patient whose flare presented with severe pleupneumonitis and myopericarditis and, following nonresponse to a methylprednisolone pulse, high dose of prednisone and cyclosporine A, recovered after a 2-day 1g/kg/day IVIG infusion.


Asunto(s)
Inmunoglobulinas Intravenosas/uso terapéutico , Factores Inmunológicos/uso terapéutico , Miocarditis/tratamiento farmacológico , Miocarditis/etiología , Pericarditis/tratamiento farmacológico , Pericarditis/etiología , Pleuroneumonía/tratamiento farmacológico , Pleuroneumonía/etiología , Enfermedad de Still del Adulto/complicaciones , Enfermedad de Still del Adulto/tratamiento farmacológico , Humanos , Masculino , Persona de Mediana Edad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...